Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
NCT ID: NCT00984529
Last Updated: 2011-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2009-09-30
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
NCT00634309
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
NCT06299826
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
NCT00634712
The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure
NCT04688294
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
NCT02887183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Cardiologist´s office patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients treated for at least 6 months with candesartan cilexetil
* Signed Informed consent
Exclusion Criteria
* Pregnancy / lactation
* Severe hepatic impairment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Biograd na Moru, , Croatia
Research Site
Bjelovar, , Croatia
Reserach Site
Čakovec, , Croatia
Research Site
Karlovac, , Croatia
Reserach Site
Krapinske Toplice, , Croatia
Research Site
Novi Marof, , Croatia
Research Site
Opatija, , Croatia
Research Site
Osijek, , Croatia
Research Site
Pula, , Croatia
Research Site
Rijeka, , Croatia
Reserach Site
Sl. Brod, , Croatia
Research Site
Split, , Croatia
Research Site
Stubičke Toplice, , Croatia
Reserach Site
Zabok, , Croatia
Research Site
Zagreb, , Croatia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CHR-ATA-2008/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.